AKAP9 antibody (AA 17-130)

Catalog No. ABIN968571

This anti-AKAP9 antibody is a Mouse Monoclonal antibody detecting AKAP9 in WB and IF. Suitable for Human. This Primary Antibody has been cited in 3+ publications.

Quick Overview for AKAP9 antibody (AA 17-130) (ABIN968571)

Target: AKAP9 (A Kinase (PRKA) Anchor Protein (Yotiao) 9 (AKAP9))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This AKAP9 antibody is un-conjugated

Application: Western Blotting (WB), Immunofluorescence (IF)

Clone: 7-AKAP450

Product Details anti-AKAP9 Antibody

Binding Specificity: AA 17-130

Characteristics: 1. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
2. Please refer to us for technical protocols.
3. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
4. Source of all serum proteins is from USDA inspected abattoirs located in the United States.

Purification: The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography.

Immunogen: Human AKAP450 aa. 17-130

Isotype: IgG1

Application Details

Comment:

Related Products: ABIN968537, ABIN967389

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 250 μg/mL

Buffer: Aqueous buffered solution containing BSA, glycerol, and ≤0.09 % sodium azide.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: -20 °C

Storage Comment: Store undiluted at -20°C.

References for anti-AKAP9 antibody (ABIN968571)

Westphal, Tavalin, Lin, Alto, Fraser, Langeberg, Sheng, Scott: "Regulation of NMDA receptors by an associated phosphatase-kinase signaling complex." in: Science (New York, N.Y.), Vol. 285, Issue 5424, pp. 93-6, (1999) (PubMed).

Witczak, Skålhegg, Keryer, Bornens, Taskén, Jahnsen, Orstavik: "Cloning and characterization of a cDNA encoding an A-kinase anchoring protein located in the centrosome, AKAP450." in: The EMBO journal, Vol. 18, Issue 7, pp. 1858-68, (1999) (PubMed).

Lin, Wyszynski, Madhavan, Sealock, Kim, Sheng: "Yotiao, a novel protein of neuromuscular junction and brain that interacts with specific splice variants of NMDA receptor subunit NR1." in: The Journal of neuroscience : the official journal of the Society for Neuroscience, Vol. 18, Issue 6, pp. 2017-27, (1998) (PubMed).

Target Details for AKAP9

Target: AKAP9 (A Kinase (PRKA) Anchor Protein (Yotiao) 9 (AKAP9))

Alternative Name: AKAP450

Background: Compartmentalization of the type II cAMP-dependent protein kinase (PKA) within the cell is essential for its discrete physiological effects. PKA localization is mediated by interactions between the regulatory (RII) subunit and A-kinase anchoring proteins (AKAPs) which position PKA in close proximity to relevant substrates. Some AKAPs exhibit tissue specific expression, while others are detected ubiquitously. AKAP450 localizes PKA type II to centrosomes. The N-terminal portion of AKAP450 (amino acids 1-1626) is almost identical to the Yotiao protein (~210 kDa), an AKAP that localizes PKA to NMDA receptors. In addition, AKAP450 contains three major regions (cc1, cc2, cc3) of coiled coil structures, which are characteristic features of centrosomeal proteins. It is expressed at low levels in multiple tissues, including skeletal muscle and liver, but is highly expressed in kidney. PKA is thought to be involved in the maintenance of the interphase microtubule network and to be necessary for stabilization of minus-end microtubules that originate from the centrosome. Thus AKAP450 may serve as a scaffolding protein to localize PKA and other signaling molecules together in cetrosomes. This antibody is routinely tested by western blot analysis.

Molecular Weight: 450 kDa

Pathways: M Phase, SARS-CoV-2 Protein Interactome